Introduction of diabetic nephropathy
出自KMU Wiki
(修訂版本間差異)
在2018年3月27日 (二) 12:42所做的修訂版本 (編輯) Guhjy (對話 | 貢獻) ←上一個 |
在2018年3月27日 (二) 12:42所做的修訂版本 (編輯) (撤銷) Guhjy (對話 | 貢獻) 下一個→ |
||
第11行: | 第11行: | ||
***Type 2 DM | ***Type 2 DM | ||
**Intensive glycemic control prevents microangiopathy in newly diagnosed DM, but effects on macroangiopathy (cardiovascular diseases and atherosclerosis) are less certain | **Intensive glycemic control prevents microangiopathy in newly diagnosed DM, but effects on macroangiopathy (cardiovascular diseases and atherosclerosis) are less certain | ||
- | *Other risk factors of DN | ||
- | **Hypertension (HT), proteinuria, smoking, hyperlipidemia, genetics (family history, renin-angiotensin gene polymorphism) |
在2018年3月27日 (二) 12:42所做的修訂版本
- The most common cause of incident ESRD and the 2nd commonest cause of prevalent ESRD in Taiwan
- Prevalence
- 40% in type 1 and 2 DM
- Because type 2 DM is much more common than type 1 DM, most diabetic nephropathy patients have type 2 DM
- Importance of hyperglycemia in DN
- DCCT (Diabetes Control and Complications Trial)
- UKPDS (UK Prospective Diabetes Study)
- Intensive glycemic control prevents microangiopathy in newly diagnosed DM, but effects on macroangiopathy (cardiovascular diseases and atherosclerosis) are less certain